Your Liver Is Talking to Your Arteries

Key Takeaway: Three readily available, non-invasive liver biomarkers—measuring fat accumulation, scarring, and organ function—independently predict the future risk of heart disease and stroke. When all three markers are elevated, the risk increases 2.5-fold compared to individuals with healthy values. This finding underscores the urgent need to incorporate liver health into routine cardiovascular risk assessment.

Loud Warnings from a Silent Organ

Long before any symptoms emerge—before the onset of fatigue, abdominal discomfort, or jaundice—the liver can begin to fail in silence. Fat infiltrates its tissue. Scar tissue replaces functioning cells. Metabolic machinery begins to falter. Most people are completely unaware this is happening. But what makes this story urgent is this: this silent decline doesn’t just threaten the liver. It is also one of the most powerful, and most overlooked, predictors of whether a person will suffer a heart attack or stroke in the years to come.

A large new prospective study quantifies this relationship with striking clarity, and its implications for how we screen patients are practice-changing.

What Did the Researchers Do?

Researchers followed 318,308 participants for a median of 14.0 years, tracking three non-invasive liver biomarkers derived from routine blood tests while observing the development of cardiovascular disease (CVD). Each of these biomarkers reflects a different dimension of liver health. The Fatty Liver Index (FLI) estimates hepatic steatosis, the amount of fat accumulated in liver cells. The Fibrosis-4 Index (FIB-4) gauges fibrosis, or the degree of scarring within the liver. The Albumin-Bilirubin (ALBI) score reflects overall hepatic function by measuring the liver’s ability to synthesize proteins and clear waste products^[1].

None of these scores requires imaging or a liver biopsy. They are calculated from standard laboratory parameters that clinicians already routinely order, such as triglycerides, ALT, platelets, albumin, bilirubin, and body mass index. The question was simple: could these markers, alone or in combination, predict who would develop cardiovascular disease?

What Did They Find?

The answer was clear and definitive. Each biomarker independently predicted new-onset CVD, even after adjusting for traditional cardiovascular risk factors. Compared to participants in the lowest quartile, the adjusted hazard ratio for those in the highest FLI quartile was 1.46. For FIB-4, the ratio in the highest quartile was 1.66. For ALBI, it was 1.42. Each of these associations held true even after controlling for traditional risk factors that dominate current screening tools, such as age, sex, smoking, diabetes, hypertension, and cholesterol.

But the most striking finding was the synergistic effect. Participants in the highest quartile for all three biomarkers—meaning they had significant liver fat, fibrosis, and dysfunction concurrently—faced an adjusted hazard ratio of 2.53 (95% CI 2.38–2.70) for developing cardiovascular disease. This represents a 153% increase in risk compared to those with the healthiest liver profiles. The study also revealed sex-based differences: FLI had a stronger association with CVD in women, while FIB-4 and ALBI showed greater predictive power in men.

Why the Liver and Heart Are Inextricably Linked

To understand why a diseased liver heralds a diseased heart, one must grasp the liver’s central role in metabolic regulation. The liver is the body’s largest metabolic organ, responsible for processing lipids, producing cholesterol, regulating glucose homeostasis, and clearing inflammatory mediators from the bloodstream^[2].

When fat begins to accumulate in hepatocytes, the hallmark of non-alcoholic fatty liver disease (NAFLD), a cascade of metabolic dysregulation is triggered. Insulin resistance deepens. The liver overproduces very-low-density lipoprotein (VLDL) particles, flooding the bloodstream with atherogenic lipoproteins that accelerate plaque buildup in coronary and cerebral arteries^[3]. Simultaneously, the fatty liver becomes a factory for pro-inflammatory cytokines such as interleukin-6, tumor necrosis factor-alpha, and C-reactive protein. These are the very inflammatory molecules implicated in atherosclerotic plaque instability and rupture^[4].

As steatosis progresses to fibrosis, the damage compounds. Hepatic stellate cells become activated, depositing collagen and distorting the liver’s architecture. Portal hypertension develops. The liver’s ability to synthesize albumin—a protein critical for maintaining vascular integrity and transporting hormones—diminishes. Bilirubin clearance falters. The production of clotting factors becomes dysregulated, creating a prothrombotic state that further elevates cardiovascular risk^[5].

This is the cardio-hepatic-metabolic axis at work: a vicious cycle where liver dysfunction drives systemic inflammation, dyslipidemia, insulin resistance, and endothelial damage, all converging on the vascular system.

Key Limitations

No single study, no matter how large, rewrites clinical guidelines overnight. This is an observational cohort study, meaning it can identify associations but cannot establish definitive causation. The biomarkers, while validated, are indirect measures—FLI estimates steatosis without imaging confirmation, and FIB-4 approximates fibrosis without a biopsy. Residual confounding from unmeasured variables such as dietary quality, physical activity habits, and subclinical alcohol intake is always a possibility. Furthermore, the sex-based differences in biomarker performance need to be replicated in diverse populations before they can inform sex-specific screening strategies.

Conclusion: What This Means for You

The practical message from this research is both simple and urgent. Three scores derived from blood tests can identify individuals at significantly high cardiovascular risk who might be missed by traditional screening. A person with a normal cholesterol panel and normal blood pressure can still have a fatty, fibrotic, and dysfunctional liver that doubles their risk of a future cardiovascular event.

For clinicians, this study suggests it’s time to stop treating the liver and the heart as separate organ systems with separate risk assessments. Calculating FLI, FIB-4, and ALBI adds no cost to a standard metabolic panel—the data are already there in the electronic health record, waiting to be interpreted. For patients, the takeaway is equally clear: if your doctor mentions your liver enzymes are “a little high” or an ultrasound shows your liver looks “a bit fatty,” do not dismiss it as an incidental finding. That liver is talking to your blood vessels, and the conversation may be far more dangerous than anyone realizes.

Scientific Sources

1. Li L, et al. Subclinical liver disease and incident cardiovascular events. European heart journal. 2026. PubMed: https://pubmed.ncbi.nlm.nih.gov/42702521/
2. Trefts E, et al. The liver. Curr Biol. 2017. DOI: 10.1016/j.cub.2017.09.019
3. Targher G, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016. DOI: 10.1016/j.jhep.2016.05.013
4. Tilg H, et al. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2022. DOI: 10.1136/gutjnl-2020-320622
5. Tsochatzis EA, et al. Liver cirrhosis. Lancet. 2014. DOI: 10.1016/S0140-6736(14)60121-5